{
    "Trade/Device Name(s)": [
        "ST AIA-PACK BNP Assay"
    ],
    "Submitter Information": "Tosoh Bioscience, Inc.",
    "510(k) Number": "K211199",
    "Predicate Device Reference 510(k) Number(s)": [
        "K192380"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBC"
    ],
    "Summary Letter Date": "April 20, 2021",
    "Summary Letter Received Date": "April 22, 2021",
    "Submission Date": "April 20, 2021",
    "Regulation Number(s)": [
        "21 CFR 862.1117"
    ],
    "Regulation Name(s)": [
        "B-Type Natriuretic Peptide Test System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "B-type Natriuretic Peptide (BNP)"
    ],
    "Specimen Type(s)": [
        "Human K2EDTA plasma"
    ],
    "Specimen Container(s)": [
        "K2EDTA tube",
        "Sample cups"
    ],
    "Instrument(s)/Platform(s)": [
        "Tosoh AIA Analyzer 2000",
        "Tosoh AIA System Analyzers"
    ],
    "Method(s)/Technology(ies)": [
        "Immunoenzymometric assay",
        "Fluorescence"
    ],
    "Methodologies": [
        "Sandwich assay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Kit"
    ],
    "Document Summary": "FDA 510(k) summary for Tosoh ST AIA-PACK BNP immunoenzymometric assay for BNP measurement in plasma with dilution claims",
    "Indications for Use Summary": "Quantitative measurement of BNP in human (K2EDTA) plasma as an aid in diagnosing heart failure in ED patients with suspected new onset or exacerbated heart failure",
    "fda_folder": "Clinical Chemistry"
}